Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2011

01-02-2011 | Original Article

Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer

Authors: Katsuhiro Masago, Shiro Fujita, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Kaoru Irisa, Hiroki Nagai, Yuichi Sakamori, Yosuke Togashi, Tadashi Mio, Michiaki Mishima

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2011

Login to get access

Abstract

Purpose

The objectives of this phase I trial were to evaluate the toxicity of the nedaplatin/gemcitabine regimen, determine the maximum tolerated doses (MTDs) of these agents, and observe the anti-tumor effects of this regimen on advanced squamous cell lung cancer.

Methods

Patients with previously untreated advanced squamous cell lung cancer were eligible if they had a performance status of 0 or 1 with adequate organ function. The doses of gemcitabine (days 1 and 8) and nedaplatin (day 8) studied were 800/70, 1,000/80, 1,000/90, and 1,000/100 (mg/m2), repeated every 3 weeks.

Results

Toxicity and response could be assessed in all 13 patients enrolled. The patients included 12 men and one woman with a median age of 69 years (range 57–81 years). Three patients had stage IIIB disease and 10 patients had stage IV disease. The MTDs were reached at 1,000 mg/m2 gemcitabine and 80 mg/m2 nedaplatin. The most frequent toxic effects were thrombocytopenia and neutropenia; grade 3 or 4 thrombocytopenia was observed in 23% of patients, and grade 3 or 4 neutropenia was seen in 46% of patients. Non-hematologic toxicities were mild. Grade 3 fatigue, nausea/vomiting, and appetite loss occurred in two patients. The overall response rate was 62%.

Conclusions

We recommend doses of 800 mg/m2 gemcitabine and 70 mg/m2 nedaplatin for phase II study. This combination chemotherapeutic regimen is active and well tolerated.
Literature
1.
Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. J Clin Oncol 26:60–65CrossRefPubMed
2.
Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H (2002) Rowinsky EK: Zd1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240–2250CrossRefPubMed
3.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132CrossRefPubMed
4.
Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M (1990) Nephrotoxicity of a new platinum compound, 254-s, evaluated with rat kidney cortical slices. Toxicol Lett 52:15–24CrossRefPubMed
5.
Ota K, Wakui A, Majima H, Niitani H, Inuyama Y, Ogawa M, Ariyoshi Y, Yoshida O, Taguchi T, Kimura I et al (1992) Phase I study of a new platinum complex 254-s, cis-diammine (glycolato)-platinum (ii). Gan To Kagaku Ryoho 19:855–861PubMed
6.
Kelsen DP, Scher H, Alcock N, Leyland-Jones B, Donner A, Williams L, Greene G, Burchenal JH, Tan C, Philips FS, Young CW (1982) Phase I clinical trial and pharmacokinetics of 4′-carboxyphthalato(1, 2-diaminocyclohexane)platinum(ii). Cancer Res 42:4831–4835PubMed
7.
Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolate-o, o′) diammineplatinum(ii), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393–396CrossRefPubMed
8.
Furuse K, Fukuoka M, Asamoto H, Niitani H, Kimura I, Sakuma A, Yamaguchi Y (1992) a randomized comparative study of 254-s plus vindesine (vds) vs. Cisplatin (cddp) plus vds in patients with advanced non-small cell lung cancer (nsclc). Gan To Kagaku Ryoho 19:1019–1026PubMed
9.
Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6(Suppl 6):7–13CrossRefPubMed
10.
Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL (2001) Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine. Ann Oncol 12:1221–1230CrossRefPubMed
11.
Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J (2000) Gemcitabine plus best supportive care (bsc) vs bsc in inoperable non-small cell lung cancer–a randomized trial with quality of life as the primary outcome. Uk nsclc gemcitabine group. Non-small cell lung cancer. Br J Cancer 83:447–453CrossRefPubMed
12.
Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1821–1826PubMed
13.
Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A:243–248CrossRefPubMed
14.
Sandler A, Ettinger DS (1999) Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4:241–251PubMed
15.
Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Gentile M, Marzano N, Gravina A, Dimitri P, Costagliola G, Ferraro A, Ferrante G, De Marino V, Illiano A (1999) Phase I–II study of gemcitabine and carboplatin in stage iiib–iv non-small-cell lung cancer. J Clin Oncol 17:921–926PubMed
16.
Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Ohmori T, Saijo N (1991) Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay. Cancer Chemother Pharmacol 27:263 270
17.
Ikeda M, Maekawa R, Tanaka H, Matsumoto M, Takeda Y, Tamura Y, Nemori R, Yoshioka T (2000) Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clin Cancer Res 6:3290–3296PubMed
18.
Matsumoto M, Takeda Y, Maki H, Hojo K, Wada T, Nishitani Y, Maekawa R, Yoshioka T (2001) Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res 92:51–58PubMed
19.
Takeda Y, Wada T, Nishitani Y, Matsumoto M, Hojo K, Maekawa R, Yoshioka T (2002) Preclinical combination chemotherapy of nedaplatin with gemcitabine against gemcitabine-refractory human lung cancer. Cancer Lett 182:61–68CrossRefPubMed
20.
Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M (2009) Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. BMC Cancer 9:408CrossRefPubMed
21.
Masters GA, Argiris AE, Hahn EA, Beck JT, Rausch PG, Ye Z, Monberg MJ, Bloss LP, Curiel RE, Obasaju CK (2006) A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. J Thorac Oncol 1:19–24CrossRefPubMed
22.
Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C, Franco Conte P (2000) A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma. Cancer 89:1714–1719CrossRefPubMed
23.
Hirose T, Horichi N, Ohmori T, Shirai T, Sohma S, Yamaoka T, Ohnishi T, Adachi M (2003) Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer. Lung Cancer 39:91–97CrossRefPubMed
24.
Kurata T, Tamura K, Yamamoto N, Nogami T, Satoh T, Kaneda H, Nakagawa K, Fukuoka M (2004) Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer 90:2092–2096PubMed
25.
Shirai T, Hirose T, Noda M, Ando K, Ishida H, Hosaka T, Ozawa T, Okuda K, Ohnishi T, Ohmori T, Horichi N, Adachi M (2006) Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer. Lung Cancer 52:181–187CrossRefPubMed
26.
Niioka T, Uno T, Yasui-Furukori N, Takahata T, Shimizu M, Sugawara K, Tateishi T (2007) Pharmacokinetics of low-dose nedaplatin and validation of auc prediction in patients with non-small-cell lung carcinoma. Cancer Chemother Pharmacol 59:575–580CrossRefPubMed
27.
Yamamoto N, Tamura T, Kurata T, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Saijo N (2009) A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65:79–88CrossRefPubMed
Metadata
Title
Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer
Authors
Katsuhiro Masago
Shiro Fujita
Young Hak Kim
Yukimasa Hatachi
Akiko Fukuhara
Kaoru Irisa
Hiroki Nagai
Yuichi Sakamori
Yosuke Togashi
Tadashi Mio
Michiaki Mishima
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1321-1

Other articles of this Issue 2/2011

Cancer Chemotherapy and Pharmacology 2/2011 Go to the issue

Short Communication

The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines

Original Article

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Original Article

Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability

Original Article

Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N

Original Article

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

Original Article

A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits